NCT05392946View on ClinicalTrials.gov

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Plasma Cell Myeloma
Interventions
DRUG

Bortezomib

Given SC

BIOLOGICAL

Daratumumab

Given SC

DRUG

Dexamethasone

Given PO

DRUG

Iberdomide

Given PO

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05392946 - Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | Biotech Hunter | Biotech Hunter